Terns Pharmaceuticals Management
Management criteria checks 2/4
Terns Pharmaceuticals' CEO is Senthil Sundaram, appointed in Jul 2020, has a tenure of 2.33 years. total yearly compensation is $3.13M, comprised of 16.4% salary and 83.6% bonuses, including company stock and options. directly owns 0.02% of the company’s shares, worth €36.68K. The average tenure of the management team and the board of directors is 2 years and 1.9 years respectively.
Key information
Senthil Sundaram
Chief executive officer
US$3.1m
Total compensation
| CEO salary percentage | 16.4% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.02% |
| Management average tenure | 2yrs |
| Board average tenure | 1.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$59m |
| Jun 30 2022 | n/a | n/a | -US$54m |
| Mar 31 2022 | n/a | n/a | -US$51m |
| Dec 31 2021 | US$3m | US$514k | -US$50m |
| Sep 30 2021 | n/a | n/a | -US$35m |
| Jun 30 2021 | n/a | n/a | -US$35m |
| Mar 31 2021 | n/a | n/a | -US$34m |
| Dec 31 2020 | US$14m | US$208k | -US$29m |
Compensation vs Market: Senthil's total compensation ($USD3.13M) is above average for companies of similar size in the German market ($USD603.52K).
Compensation vs Earnings: Senthil's compensation has been consistent with company performance over the past year.
CEO
Senthil Sundaram (44 yo)
2.3yrs
Tenure
US$3,126,295
Compensation
Mr. Senthil Vel Sundaram serves as Independent Director at Social Capital Suvretta Holdings Corp. I since September 24, 2021. He has been Chief Executive Officer and Director of Terns Pharmaceuticals, Inc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$3.13m | 0.020% € 36.7k | |
| President & Head of Research & Development | 2.4yrs | US$1.69m | 0% € 0 | |
| COO, General Counsel & Secretary | 2yrs | US$1.48m | 0.020% € 36.7k | |
| Co-Founder & Executive Officer | no data | no data | 0.76% € 1.4m | |
| CFO & Treasurer | 2.3yrs | US$3.46m | 0.020% € 36.7k | |
| Senior VP & Head of Research | less than a year | no data | no data | |
| Senior VP & Chief Development Officer | less than a year | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
2.0yrs
Average Tenure
44yo
Average Age
Experienced Management: 430's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$3.13m | 0.020% € 36.7k | |
| Independent Director | 4.1yrs | US$365.54k | 0% € 0 | |
| Independent Director | 1.9yrs | US$196.91k | 0% € 0 | |
| Independent Director | 2.6yrs | US$373.33k | 0% € 0 | |
| Member of Scientific Advisor | no data | no data | no data | |
| Independent Chairman | 1.9yrs | US$220.29k | 0% € 0 | |
| Member of Scientific Advisor | no data | no data | no data | |
| Member of Scientific Advisor | no data | no data | no data | |
| Director | less than a year | no data | no data | |
| Member of Scientific Advisor | no data | no data | no data | |
| Independent Director | 1.9yrs | US$198.29k | 0% € 0 | |
| Independent Director | 1.2yrs | US$320.09k | no data |
1.9yrs
Average Tenure
53.5yo
Average Age
Experienced Board: 430's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/11/13 14:25 |
| End of Day Share Price | 2022/08/16 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Terns Pharmaceuticals, Inc. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | BMO Capital Markets Equity Research |
| Corinne Johnson | Goldman Sachs |
| Corinne Johnson | Goldman Sachs |